QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   903.50 (+0.11%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.20 (+1.07%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.27 (-2.69%)
DIS   122.35 (+1.13%)
AMC   3.65 (-15.90%)
PFE   27.86 (+0.29%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

$33.75
+0.89 (+2.71%)
(As of 03:04 PM ET)
Today's Range
$32.00
$33.75
50-Day Range
$31.72
$42.99
52-Week Range
$17.52
$43.81
Volume
200,803 shs
Average Volume
437,919 shs
Market Capitalization
$908.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.71

Arcturus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.8% Upside
$57.71 Price Target
Short Interest
Bearish
17.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Arcturus Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$910,434 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.42) to $5.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

540th out of 938 stocks

Pharmaceutical Preparations Industry

251st out of 433 stocks

ARCT stock logo

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

ARCT Stock Price History

ARCT Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
ARCT Apr 2024 30.000 call
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Recap: Arcturus Therapeutics Q4 Earnings
ARCT Sep 2024 30.000 put
Earnings Preview: Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc (ARCT)
See More Headlines
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$57.71
High Stock Price Target
$90.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+79.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-29,730,000.00
Pretax Margin
-16.72%

Debt

Sales & Book Value

Annual Sales
$169.93 million
Book Value
$10.42 per share

Miscellaneous

Free Float
23,201,000
Market Cap
$867.09 million
Optionable
Optionable
Beta
2.64
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joseph E. Payne M.Sc. (Age 52)
    Founder, President, CEO & Director
    Comp: $1.13M
  • Mr. Andrew H. Sassine MBA (Age 60)
    CFO & Director
    Comp: $826.88k
  • Ms. Neda Safarzadeh
    Vice President and Head of IR/PR & Marketing
  • Mr. Lance Kurata
    Chief Legal Officer
  • Ms. Natash O. Bowman
    Chief Human Resources Officer
  • Mr. Kevin T. Skol
    Chief Business Officer
  • Dr. Juergen Froehlich FCPh (Age 68)
    M.D., MBA, Chief Medical Officer
  • Dr. Igor Smolenov M.D.
    Ph.D., Chief Development Officer

ARCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month price objectives for Arcturus Therapeutics' shares. Their ARCT share price targets range from $36.00 to $90.00. On average, they predict the company's share price to reach $57.71 in the next year. This suggests a possible upside of 72.8% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2024?

Arcturus Therapeutics' stock was trading at $31.53 at the beginning of the year. Since then, ARCT stock has increased by 5.9% and is now trading at $33.39.
View the best growth stocks for 2024 here
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARCT earnings forecast
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.40) by $0.65. The biotechnology company earned $2.44 million during the quarter, compared to the consensus estimate of $26.70 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 18.22%. During the same period in the previous year, the business earned ($0.92) EPS.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.66%), Vanguard Group Inc. (5.46%), Vanguard Group Inc. (5.46%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.94%) and Dimensional Fund Advisors LP (4.08%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARCT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners